

CVS CAREMARK CORP  
Form 8-K  
August 12, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 7, 2014**

**CVS CAREMARK CORPORATION**

**(Exact Name of Registrant as Specified in its Charter)**

**Delaware**  
**(State or Other Jurisdiction**

**of Incorporation)**

**001-01011**

**05-0494040**

**(Commission**

**(IRS Employer**

**File Number)**

**Identification No.)**

**One CVS Drive**

**Woonsocket, Rhode Island**

**(Address of Principal Executive  
Offices)**

**02895**

**(Zip Code)**

**Registrant's telephone number, including area code: (401) 765-1500**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

### **Item 8.01. Other Events.**

On August 7, 2014, CVS Caremark Corporation, a Delaware corporation (the *Company*), entered into an Underwriting Agreement (the *Underwriting Agreement*) with Barclays Capital Inc. and Merrill Lynch, Pierce, Fenner & Smith Incorporated, as representatives of the several underwriters named in Schedule I thereto (the *Underwriters*), pursuant to which the *Company* agreed to issue and sell to the *Underwriters* \$850,000,000 aggregate principal amount of its 2.250% senior notes due August 12, 2019 (the *2019 Notes*) and \$650,000,000 aggregate principal amount of its 3.375% senior notes due August 12, 2024 (the *2024 Notes*), collectively (the *Notes*). The *Notes* were offered pursuant to the *Company*'s Registration Statement on Form S-3, File No. 333-187440, dated March 21, 2013.

From time to time, certain of the *Underwriters* and/or their respective affiliates have directly and indirectly engaged, and may engage in the future, in investment and/or commercial banking transactions with the *Company* for which they have received, or may receive, customary compensation, fees and expense reimbursement. Barclays Capital Inc. and RBS Securities Inc. are acting as Dealer Managers in connection with the *Company*'s cash tender offers (the *Tender Offers*) for its 6.250% Senior Notes due 2027, 6.125% Senior Notes due 2039, 5.750% Senior Notes due 2041 and 5.750% Senior Notes due 2017. To the extent any of the *Underwriters* or their affiliates own notes that are the subject of the *Tender Offers*, they may tender such notes pursuant to the terms of the *Tender Offers*. An affiliate of one of the underwriters, BNY Mellon Capital Markets, LLC, is the trustee, registrar and paying agent for the *Notes*. Additionally, a member of the *Company*'s board of directors is an officer of Bank of America Corporation, an affiliate of one of the *Underwriters*.

The closing of the sale of the *Notes* will occur on August 12, 2014. The net proceeds to the *Company* from the sale of the *Notes*, after deducting the *Underwriters*' discounts and the estimated offering expenses payable by the *Company*, are approximately \$1,482,069,650. A copy of the *Underwriting Agreement* is filed as Exhibit 1.1 to this report on Form 8-K and is incorporated by reference into the Registration Statement.

The *Notes* will be governed by and issued pursuant to a Senior Indenture dated August 15, 2006 between the *Company* and The Bank of New York Mellon Trust Company, N.A., as trustee (the *Senior Indenture*). The *Company* may issue additional senior debt securities from time to time pursuant to the *Senior Indenture*. The form of *Senior Indenture* was filed as Exhibit 4.1 to the *Company*'s Current Report on Form 8-K filed August 15, 2006 and shall be incorporated by reference into this report on Form 8-K. Forms of the *Notes* are filed as Exhibit 4.1 and 4.2 to this report on Form 8-K and are incorporated by reference into the Registration Statement.

### **Item 9.01 Financial Statements and Exhibits.**

#### **(d) Exhibits**

- 1.1** Underwriting Agreement dated August 7, 2014 between CVS Caremark Corporation and Barclays Capital Inc. and Merrill Lynch, Pierce, Fenner & Smith Incorporated, as representatives of the several underwriters named in Schedule I thereto
- 4.1** Form of the 2019 Note
- 4.2** Form of the 2024 Note
- 5.1** Opinion of Shearman & Sterling LLP
- 23.1** Consent of Shearman & Sterling LLP (included in Exhibit 5.1)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CVS CAREMARK CORPORATION

By: /s/ David M. Denton  
David M. Denton  
Executive Vice President and  
Chief Financial Officer

Dated: August 12, 2014